CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
NEW YORK, April 05, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Solid Biosciences Inc. ("Solid Biosciences") (NASDAQ:SLDB) pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra-d/solid-biosciences-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Solid Bioscience’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) the company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
If you suffered a loss in Solid Biosciences you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
